Mikael Åberg

Associate professor

Uppsala University

Sweden

Research Interests

Explore related searches

Professors in Sweden Professors in Immunology Immunology professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Mikael Åberg is an Associate Professor at Uppsala University in Sweden. His research focuses on immunological responses related to SARS-CoV-2 vaccination, proteomics in infectious diseases, and biomarker profiling in various medical conditions. Recent publications include studies on mucosal IgA responses, plasma protein biomarkers in malaria, and the assessment of immunogenicity in immunocompromised individuals following mRNA vaccination.

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (14)

Sophia Hober

Professor

KTH Royal Institute of Technology

SWEDEN

View details

Ali Rihani

Karolinska Institutet

SWEDEN

View details

Adil Mardinoglu

Professor

King’s College London

UNITED KINGDOM

View details

María Bueno Álvez

KTH Royal Institute of Technology

SWEDEN

View details

Tobias Sjöblom

Professor at Uppsala University

Uppsala University

SWEDEN

View details

stephan ripke

Charité - Universitätsmedizin Berlin

GERMANY

View details

Anders F Johansson

Full Professor

Umeå Universitet Medicinska fakulteten

SWEDEN

View details

Micael Widerström

Ass professor, MD, PhD

Umeå Universitet Medicinska fakulteten

SWEDEN

View details

Jessica Alm

Head of Unit

Karolinska Institutet

SWEDEN

View details

Max Gordon

Karolinska Institutet

SWEDEN

View details

Oscar Bladh

Karolinska Institutet

SWEDEN

View details

Jonas Klingstrom

Karolinska Institutet

SWEDEN

View details

Martin Driessen

Bielefeld University

GERMANY

View details

Margaret Sällberg Chen

Karolinska Institutet

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mikael Åberg

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Impact of systemic SARS-CoV-2 vaccination on mucosal IgA responses to subsequent breakthrough infection

Plasma protein biomarkers of <i>Plasmodium falciparum</i> infection in pregnant women: a high-throughput proteomics study.

Proteomic signatures for fibrosis in MASLD: a biopsy-proven dual-cohort study

Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum.

Prevalence of SARS-CoV-2 infections among Swedish healthcare workers on duty in December 2023.

Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.

Plasma H3Cit-DNA Discriminates Between Cancer and Inflammation in a Cohort of Patients with Unspecific Cancer Symptoms.

A stratified treatment algorithm in psychiatry: a program on stratified pharmacogenomics in severe mental illness (Psych-STRATA): concept, objectives and methodologies of a multidisciplinary project funded by Horizon Europe.

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID.

Monitoring SARS-CoV-2 IgA, IgM and IgG antibodies in dried blood and saliva samples using antibody proximity extension assays (AbPEA).

Next generation pan-cancer blood proteome profiling using proximity extension assay

SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters.

Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia.

Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia.

Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection.

Mucosal IgA protects against BQ.1 and BQ.1.1 infection.

Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21).

Collaborators (14)

Sophia Hober

Ali Rihani

Adil Mardinoglu

María Bueno Álvez

Tobias Sjöblom

stephan ripke

Anders F Johansson

Micael Widerström

Jessica Alm

Max Gordon

Oscar Bladh

Jonas Klingstrom

Martin Driessen

Margaret Sällberg Chen

Make your next move.

Mikael Åberg

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Impact of systemic SARS-CoV-2 vaccination on mucosal IgA responses to subsequent breakthrough infection

Plasma protein biomarkers of &lt;i&gt;Plasmodium falciparum&lt;/i&gt; infection in pregnant women: a high-throughput proteomics study.

Proteomic signatures for fibrosis in MASLD: a biopsy-proven dual-cohort study

Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum.

Prevalence of SARS-CoV-2 infections among Swedish healthcare workers on duty in December 2023.

Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.

Plasma H3Cit-DNA Discriminates Between Cancer and Inflammation in a Cohort of Patients with Unspecific Cancer Symptoms.

A stratified treatment algorithm in psychiatry: a program on stratified pharmacogenomics in severe mental illness (Psych-STRATA): concept, objectives and methodologies of a multidisciplinary project funded by Horizon Europe.

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID.

Monitoring SARS-CoV-2 IgA, IgM and IgG antibodies in dried blood and saliva samples using antibody proximity extension assays (AbPEA).

Next generation pan-cancer blood proteome profiling using proximity extension assay

SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters.

Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia.

Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia.

Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection.

Mucosal IgA protects against BQ.1 and BQ.1.1 infection.

Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21).

Collaborators (14)

Sophia Hober

Ali Rihani

Adil Mardinoglu

María Bueno Álvez

Tobias Sjöblom

stephan ripke

Anders F Johansson

Micael Widerström

Jessica Alm

Max Gordon

Oscar Bladh

Jonas Klingstrom

Martin Driessen

Margaret Sällberg Chen

Make your next move.

Plasma protein biomarkers of <i>Plasmodium falciparum</i> infection in pregnant women: a high-throughput proteomics study.